Met Life Investment Management, LLC Nektar Therapeutics Transaction History
Met Life Investment Management, LLC
- $17.1 Billion
- Q3 2024
A detailed history of Met Life Investment Management, LLC transactions in Nektar Therapeutics stock. As of the latest transaction made, Met Life Investment Management, LLC holds 106,506 shares of NKTR stock, worth $113,961. This represents 0.0% of its overall portfolio holdings.
Number of Shares
106,506
Previous 46,494
129.07%
Holding current value
$113,961
Previous $57,000
142.11%
% of portfolio
0.0%
Previous 0.0%
Shares
61 transactions
Others Institutions Holding NKTR
# of Institutions
147Shares Held
139MCall Options Held
32.6KPut Options Held
14.1K-
Deep Track Capital, LP Greenwich, CT15.9MShares$17 Million0.76% of portfolio
-
Black Rock Inc. New York, NY15.2MShares$16.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.1MShares$14 Million0.0% of portfolio
-
Eventide Asset Management, LLC Boston, MA9.4MShares$10.1 Million0.22% of portfolio
-
Samlyn Capital, LLC New York, NY9.2MShares$9.84 Million0.19% of portfolio
About NEKTAR THERAPEUTICS
- Ticker NKTR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 187,404,992
- Market Cap $201M
- Description
- Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...